<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313485489</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313485489</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jovancevic</surname><given-names>B</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313485489">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203313485489"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Lindholm</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313485489">1</xref>
<xref ref-type="aff" rid="aff2-0961203313485489">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pullerits</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313485489">1</xref>
<xref ref-type="aff" rid="aff2-0961203313485489">2</xref>
<xref ref-type="aff" rid="aff3-0961203313485489">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203313485489"><label>1</label>Department of Rheumatology, Sahlgrenska University Hospital, Sweden</aff>
<aff id="aff2-0961203313485489"><label>2</label>Department of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Sweden</aff>
<aff id="aff3-0961203313485489"><label>3</label>Department of Clinical Immunology, Sahlgrenska University Hospital, Sweden</aff>
<author-notes>
<corresp id="corresp1-0961203313485489">Boja Jovancevic, Department of Rheumatology, Sahlgrenska University Hospital, Box 480, 41346, Gothenburg, Sweden. Email: <email>boja.jovancevic@vgregion.se</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>7</issue>
<fpage>664</fpage>
<lpage>674</lpage>
<history>
<date date-type="received"><day>21</day><month>7</month><year>2012</year></date>
<date date-type="accepted"><day>12</day><month>3</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec17-0961203313485489"><title>Objective</title>
<p>The objective of this study was to retrospectively evaluate the clinical and immunological effects of anti-B cell treatment in patients with systemic lupus erythematosus (SLE) and mixed connective-tissue disease (MCTD) with autoimmune thrombocytopenia (AITP) refractory to conventional immunosuppressive treatment.</p>
</sec>
<sec id="sec18-0961203313485489"><title>Methods</title>
<p>Rituximab (RTX) was added to the ongoing treatment of 16 patients (median age 36 years, range 17–84, all female) with treatment-resistant AITP. Thirteen patients had SLE and three had MCTD. RTX was given intravenously on four occasions during four consecutive weeks at a dose of 375 mg/m<sup>2</sup>. Clinical and laboratory disease activity variables recorded at every follow-up visit were analyzed.</p>
</sec>
<sec id="sec19-0961203313485489"><title>Results</title>
<p>The median disease duration before RTX treatment was nine years (range 0.2–27) and the median post-treatment follow-up time was 28 months (range 3 to 92). Ten patients (63%) were treated repeatedly with RTX during the follow-up period. Complete depletion of B cells was achieved in 94% of cases one month after RTX treatment. A significant increase (<italic>p</italic> = 0.0001) of platelet counts was seen already after one month (median 58 × 10<sup>9</sup>/ml vs 110 × 10<sup>9</sup>/ml) whereas within three months platelet counts normalized in 10 patients (median 223 × 10<sup>9</sup>/ml). Three patients did not respond to RTX treatment (median platelet count 69 × 10<sup>9</sup>/ml). High titers of anti-platelet antibodies were detected in seven patients before RTX treatment, and the autoantibody titers decreased significantly (<italic>p</italic> &lt; 0.03) after RTX treatment in six of these patients who also achieved complete remission. A review of the literature revealed 24 articles including 18 case reports, one retrospective cohort study and five prospective studies documenting the outcomes of 65 RTX-treated patients with SLE- or MCTD-related thrombocytopenia with an overall treatment response rate of 80%. In conclusion, these findings indicate that RTX is an additional potent therapeutic treatment option for SLE patients with AITP refractory to conventional immunosuppressive treatment whereas best response may be expected in patients with high titers of anti-platelet antibodies at baseline.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Systemic lupus erythematosus</kwd>
<kwd>hematologic changes</kwd>
<kwd>anti-platelet antibodies</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313485489" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) and mixed connective-tissue disease (MCTD) are complex multi-systemic autoimmune diseases with heterogeneous presentation of varying severity. SLE is characterized by polyclonal B cell hyper-reactivity that is considered to be the most important pathogenic event. The mechanism behind the abnormal B cell activation is not fully understood although disturbances in several immune regulation mechanisms have been suggested.<sup><xref ref-type="bibr" rid="bibr1-0961203313485489">1</xref></sup> The pathogenic role of B cells in SLE pathogenesis involves several pathways such as formation of auto-antibodies and immune complexes, activation of dendritic and T cells, cytokine production as well as chemokine-mediated reactions.<sup><xref ref-type="bibr" rid="bibr2-0961203313485489">2</xref></sup> MCTD, clinically presenting manifestations that overlap with SLE, scleroderma, rheumatoid arthritis or inflammatory myopathies, is immunologically characterized by the presence of auto-antibodies and T cells reactive with U1-ribonucleoprotein.<sup><xref ref-type="bibr" rid="bibr3-0961203313485489">3</xref></sup> The production of characteristic patterns of auto-antibodies, some of which are clearly involved in tissue damage, has been shown to play an important role in both SLE and MCTD.</p>
<p>Autoimmune thrombocytopenia (AITP), a common hematological manifestation of SLE, is found in 20%–40% of patients<sup><xref ref-type="bibr" rid="bibr4-0961203313485489">4</xref></sup> and results from accelerated platelet destruction mediated by auto-antibodies to platelet glycoproteins.<sup><xref ref-type="bibr" rid="bibr4-0961203313485489">4</xref></sup> Antibody-coated platelets are removed by the reticuloendothelial system, mostly in the spleen. The severe form of SLE-related immune thrombocytopenia is relatively rare,<sup><xref ref-type="bibr" rid="bibr5-0961203313485489">5</xref></sup> but is potentially life threatening and often unresponsive to standard treatment. Severe thrombocytopenia has also been shown to be an independent predictor of damage accrual and mortality.<sup><xref ref-type="bibr" rid="bibr6-0961203313485489">6</xref><xref ref-type="bibr" rid="bibr7-0961203313485489"/>–<xref ref-type="bibr" rid="bibr8-0961203313485489">8</xref></sup></p>
<p>The most common treatments for AITP are corticosteroids and intravenous immunoglobulin (IVIG).<sup><xref ref-type="bibr" rid="bibr9-0961203313485489">9</xref>,<xref ref-type="bibr" rid="bibr10-0961203313485489">10</xref></sup> However, in some SLE patients, the disease becomes either resistant to this therapy or steroid dependent, requiring the use of second-line agents or splenectomy.<sup><xref ref-type="bibr" rid="bibr11-0961203313485489">11</xref>,<xref ref-type="bibr" rid="bibr12-0961203313485489">12</xref></sup> A subset of patients, despite therapy with systemic corticosteroids and immunosuppressive agents, still remains refractory or develop unacceptable toxicity. Therefore, new effective and less toxic treatment strategies are needed.</p>
<p>Considering the multi-functional role of B-cells in the pathogenesis of these autoimmune diseases, a depletion of B cells by targeting CD20 using rituximab (RTX) has emerged as a promising treatment option in SLE. RTX has been used to successfully treat thrombocytopenia in patients with steroid-resistant disease.<sup><xref ref-type="bibr" rid="bibr13-0961203313485489">13</xref></sup> To date, there are no randomized clinical studies and only few published reports of the use of RTX in patients with SLE- or MCTD-related AITP.</p>
<p>The aim of this study was to retrospectively evaluate the long-term clinical and immunological outcomes of anti B-cell treatment in SLE and MCTD patients with AITP and review published reports regarding RTX treatment in SLE- or MCTD-related thrombocytopenia.</p>
</sec>
<sec id="sec2-0961203313485489" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0961203313485489" sec-type="subjects"><title>Patients</title>
<p>Sixteen patients were treated with RTX at the Rheumatology Clinic, Sahlgrenska University Hospital, during the period April 2002–December 2009. Thirteen patients had SLE, diagnosed according to the American College of Rheumatology criteria.<sup><xref ref-type="bibr" rid="bibr14-0961203313485489">14</xref></sup> Four of these patients also had nephritis, and three patients with SLE had anti-phospholipid antibody syndrome. Three patients fulfilled MCTD diagnosis according to classification criteria by Kasukawa et al.<sup><xref ref-type="bibr" rid="bibr15-0961203313485489">15</xref>,<xref ref-type="bibr" rid="bibr16-0961203313485489">16</xref></sup> Results from 10 patients with thrombocytopenia diagnosed during the period April 2002–November 2006 have been reported previously,<sup><xref ref-type="bibr" rid="bibr17-0961203313485489">17</xref></sup> and these patients were continuously followed-up in the present study.</p>
<p>All patients except one had failed at least one course of methylprednisolone pulse therapy and/or IVIG and high-dose corticosteroids in combination with immunosuppressive drugs. Three patients received concomitantly IVIG and all patients were treated with immunosuppressive agents such as corticosteroids (<italic>n</italic> = 15), methotrexate (<italic>n</italic> = 6), azathioprine (<italic>n</italic> = 5), cyclophosphamide (<italic>n</italic> = 1), cyclosporine (<italic>n</italic> = 2) and mycophenolate mofetil (<italic>n</italic> = 3). One patient had undergone splenectomy without improvement. The patients' main characteristics are summarized in <xref ref-type="table" rid="table1-0961203313485489">Table 1</xref>.
<table-wrap id="table1-0961203313485489" position="float"><label>Table 1</label><caption><p>Characteristics of rituximab (RTX)-treated SLE and MCTD patients with immune thrombocytopenia</p></caption>
<graphic alternate-form-of="table1-0961203313485489" xlink:href="10.1177_0961203313485489-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Patient no.</th>
<th>Age</th>
<th>DD, years</th>
<th>Follow-up, months</th>
<th>Previous treatment</th>
<th>Diagnosis and reason for RTX treatment</th>
<th>Concomitant treatment</th>
<th>RTX repeated, times, (interval between treatments, months)</th>
<th>Response and time to response, months (m)</th>
<th>Time to ITP flare, months (m)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>1</td>
<td>33</td>
<td>8</td>
<td>92</td>
<td>CS, AZA, IVIG, CYA, splenectomy</td>
<td>SLE, thrombocytopenia</td>
<td>CS, AZA or MTX, IVIG</td>
<td>4 (78, 7, 6)</td>
<td>1) No response 2) PR – 4 m 3) PR – 2 m 4) PR – 1 m</td>
<td>5 m 3 m 6 m</td>
</tr>
<tr>
<td>2</td>
<td>17</td>
<td>10</td>
<td>3<sup><xref ref-type="table-fn" rid="table-fn1-0961203313485489">a</xref></sup></td>
<td>CS,IVIG,CYA</td>
<td>SLE, thrombocytopenia</td>
<td>CS, IVIG</td>
<td>1</td>
<td>CR – 1 m</td>
<td>No flare 3 months</td>
</tr>
<tr>
<td>3</td>
<td>52</td>
<td>21</td>
<td>86</td>
<td>CS, CYC, AZA, MTX  (splenectomy)<sup>b</sup></td>
<td>SLE, thrombocytopenia,  nephritis, APS</td>
<td>CS, MTX</td>
<td>2<sup>c</sup> (65)</td>
<td>CR – 3 m</td>
<td>No flare/remission 86 months</td>
</tr>
<tr>
<td>4</td>
<td>34</td>
<td>10</td>
<td>18</td>
<td>CS, IVIG, AZA,  MTX, CYC, CYA, MMF</td>
<td>SLE, thrombocytopenia</td>
<td>CS, IVIG</td>
<td>1</td>
<td>No response</td>
<td><sup>d</sup></td>
</tr>
<tr>
<td>5</td>
<td>21</td>
<td>3</td>
<td>46</td>
<td>CYC, MMF, RTX</td>
<td>SLE, thrombocytopenia,  nephritis</td>
<td>CYA, MMF</td>
<td>4<sup>c</sup> (6, 6, 27)</td>
<td>CR – 1 m</td>
<td>No flare/remission 46 months</td>
</tr>
<tr>
<td>6</td>
<td>37</td>
<td>2</td>
<td>47</td>
<td>CS, CYC, CYA</td>
<td>SLE, thrombocytopenia, APS</td>
<td>CS, MMF</td>
<td>3 (8, 8)</td>
<td>1) CR – 2 m 2) PR – 1 m 3) CR – 1 m</td>
<td>4 m 2 m No flare/remission  31 months</td>
</tr>
<tr>
<td>7</td>
<td>30</td>
<td>10</td>
<td>46</td>
<td>CS, AZA,HCQ</td>
<td>SLE, thrombocytopenia</td>
<td>CS, AZA</td>
<td>2 (40)</td>
<td>CR – 1 m CR – 1 m</td>
<td>6 m No flare/remission  6 months</td>
</tr>
<tr>
<td>8</td>
<td>84</td>
<td>12</td>
<td>17<sup><xref ref-type="table-fn" rid="table-fn1-0961203313485489">a</xref></sup></td>
<td>CS, MTX</td>
<td>MCTD, thrombocytopenia</td>
<td>CS, MTX</td>
<td>2 (6)</td>
<td>CR – 1 m CR – 6 m</td>
<td>3 m No flare/remission  11 months</td>
</tr>
<tr>
<td>9</td>
<td>49</td>
<td>27</td>
<td>38</td>
<td>CS, CYA, AZA, IVIG</td>
<td>SLE, thrombocytopenia</td>
<td>CS, MTX</td>
<td>2 (23)</td>
<td>No response</td>
</tr>
<tr>
<td>10</td>
<td>30</td>
<td>13</td>
<td>38</td>
<td>CS, AZA</td>
<td>MCTD, thrombocytopenia</td>
<td>CS, AZA, CYA</td>
<td>2 (8)</td>
<td>CR – 2 m CR – 3 m</td>
<td>8 m no flare/remission 30 months</td>
</tr>
<tr>
<td>11</td>
<td>37</td>
<td>0.25</td>
<td>15</td>
<td>No DMARDs</td>
<td>SLE, thrombocytopenia</td>
<td>CS, AZA</td>
<td>1</td>
<td>CR – 1 m</td>
<td>No flare/remission  15 months</td>
</tr>
<tr>
<td><bold>12</bold></td>
<td>60</td>
<td>1</td>
<td>28</td>
<td>CS, MTX</td>
<td>MCTD, thrombocytopenia</td>
<td>CS, MTX</td>
<td>3 (10, 11)</td>
<td>PR – 2 m CR – 3 m CR – 1 m</td>
<td>6 m 9 m no flare/remission  7 months</td>
</tr>
<tr>
<td><bold>13</bold></td>
<td>57</td>
<td>17</td>
<td>27</td>
<td>CS,MMF,AZA</td>
<td>SLE, thrombocytopenia</td>
<td>CS, MTX</td>
<td>1</td>
<td>No response</td>
</tr>
<tr>
<td><bold>14</bold></td>
<td>45</td>
<td>0.1</td>
<td>12</td>
<td>CS, AZA</td>
<td>SLE, thrombocytopenia, APS</td>
<td>CS, AZA</td>
<td>2<sup>c</sup> (8)</td>
<td>CR – 1 m</td>
<td>No flare/remission  12 months</td>
</tr>
<tr>
<td><bold>15</bold></td>
<td>29</td>
<td>2</td>
<td>18</td>
<td>CS,AZA, CYA, MMF</td>
<td>SLE, thrombocytopenia,  nephritis</td>
<td>CS, MMF</td>
<td>1</td>
<td>CR – 1 m</td>
<td>No flare/remission  18 months</td>
</tr>
<tr>
<td><bold>16</bold></td>
<td>33</td>
<td>8</td>
<td>20</td>
<td>CS, IVIG, AZA, MMF</td>
<td>SLE, thrombocytopenia,  nephritis</td>
<td>CS, CYC→ MMF</td>
<td>1</td>
<td>CR – 1 m</td>
<td>No flare/remission  20 months</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313485489"><label>a</label><p>Patients moved and were lost for follow-up. <sup>b</sup>Patient underwent splenectomy because of traumatic bleeding three months after the second RTX cycle <sup>c</sup>RTX re-treatment was repeated due to other indication than thrombocytopenia <sup>d</sup>Patient died. SLE: systemic lupus erythematosus; MCTD: mixed connective-tissue disease; DD: disease duration; ITP: immune thrombocytopenia; DMARDs: disease-modifying anti-rheumatic drugs; AZA: azathioprine; IVIG: intravenous immunoglobulin; MMF: mycophenolate mofetil; CYA: cyclosporine; MTX: methotrexate; HCQ: hydroxychloroquine; CYC: cyclophosphamide; CS: corticosteroids; APS: antiphospholipid syndrome; CR: complete response, defined as platelet count &gt;100 × 10<sup>9</sup>/ml; PR: partial response, defined as platelet count 50–100 × 10<sup>9</sup>/ml. Remission was defined as stable platelet count &gt;150 × 10<sup>9</sup>/ml at least three months while decreasing corticosteroid dose.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec4-0961203313485489"><title>Anti-B cells treatment</title>
<p>RTX (Mabthera®) treatment was added to the ongoing immunosuppressive treatment regimen in patients who did not sufficiently respond to conventional therapy. RTX was given as four consecutive intravenous infusions once weekly at a dose of 375 mg/m<sup>2</sup> body surface. All patients except two were given premedication therapy with paracetamol (Panodil®, 1 g) orally, antihistamine klemastin (Tavegyl®, 2 mg) and hydrocortisone (Solu-Cortef®, 100 mg) intravenously according to local treatment guidelines before RTX infusion. Two patients received methylprednisolone (Solu-Medrol® 125 mg) as a premedication.</p>
</sec>
<sec id="sec5-0961203313485489"><title>Laboratory analyses</title>
<p>The clinical effect of RTX treatment in patients with thrombocytopenia was evaluated by analyses of platelet counts. All evaluations were performed at baseline and after one, three, six, 12 and 24 months following RTX treatment. Levels of antibodies against double-stranded DNA were determined by radioimmunoassay.</p>
</sec>
<sec id="sec6-0961203313485489"><title>Evaluation of anti-thrombocyte antibodies</title>
<p>For detection of anti-thrombocyte antibodies, blood samples were collected into heparinized tubes, the thrombocyte counts were determined in a cell counter (Sysmex K-4500) and thereafter the samples were washed twice with thrombocyte-buffer containing 1.85 g ethylenediaminetetraacetic acid (EDTA) in 1000 ml phosphate-buffered saline (PBS). The samples were incubated with the following antibodies: phycoerythrin (PE)-conjugated anti-human CD41a (BD Bioscience), fluorescein isothiocyanate (FITC)-labeled rabbit anti-human IgG (Fab)<sub>2</sub> and IgM (Fab)<sub>2</sub> (Dako, Glostrup, Denmark) for 30minutes at 4°C. Red blood cells were lysed using lysing solution (BD Bioscience). After washing steps the cells were suspended in 200 µl thrombocyte-buffer and analyzed on a FACScalibur (Beckton-Dickinson). The amounts of bound IgM and IgG antibodies on the surface of thrombocytes were calculated and the results expressed as a percentage of positive platelets. The samples from healthy blood donors were analyzed in parallel as negative controls in every experiment.</p>
</sec>
<sec id="sec7-0961203313485489"><title>Evaluation of circulating B cells</title>
<p>The number of circulating B cells defined as CD19+ and CD20+ lymphocytes in peripheral blood was assessed at baseline and after one, three, six, 12 and 24 months by flow cytometry in the routine analysis laboratory in the Department of Clinical Immunology at Sahlgrenska University Hospital.<sup><xref ref-type="bibr" rid="bibr17-0961203313485489">17</xref></sup> CD19+ B cells were chosen for determination of the number of circulating B cells before and after anti-CD20 treatment to avoid any possible interference of RTX with the flow cytometric assay. A minimum of 5000 cells were counted in the lymphocyte gate. The detection level of the method was 1%. Undetectable levels of CD19+ B (levels &lt;1% of the total lymphocyte population) were considered to indicate B cell depletion from the peripheral blood. Serum levels of immunoglobulin subclasses (IgG, IgM, IgA) were determined by nephelometry, and the number of circulating immunoglobulin-producing cells was determined by an enzyme-linked immunospot (ELISPOT) assay.</p>
</sec>
<sec id="sec8-0961203313485489"><title>Response criteria</title>
<p>Complete response was defined by achievement of a platelet count &gt;100 × 10<sup>9</sup>/ml or by maintaining a platelet count &gt;100 × 10<sup>9</sup>/ml. Partial response was defined if the platelet count was 50–100 × 10<sup>9</sup>/ml. Treatment failure was determined when no improvement occurred with regard to platelet counts.<sup><xref ref-type="bibr" rid="bibr18-0961203313485489">18</xref></sup> Time to response was defined as the time from the first RTX administration to the achievement of any degree of response. Remission was defined as stable platelet count &gt;150 × 10<sup>9</sup>/ml at least three months without or while tapering off corticosteroid treatment. Relapse or progression was defined as loss of response/remission criteria.</p>
</sec>
<sec id="sec9-0961203313485489"><title>Statistical analyses</title>
<p>Nonparametric methods were used for statistical evaluation of data in most cases because of small sample size and uneven distribution. Clinical measures and all laboratory data are presented as medians and 25th–75th percentiles (interquartile range (IQR)). Responses to RTX treatment at one, three, six and 12 months were compared with baseline values. Wilcoxon signed rank test for paired samples was used for comparison of different variables at baseline and follow-up. A <italic>p</italic> value &lt; 0.05 was considered as statistically significant. All analyses were performed using StatView Software version 5.0.1 (SAS Institute Inc, NY, USA).</p>
</sec>
</sec>
<sec id="sec10-0961203313485489" sec-type="results"><title>Results</title>
<sec id="sec11-0961203313485489"><title>Patients' characteristics and demographics at baseline</title>
<p>All patients were females and the median age was 34 years (range 17–84). The majority of patients were Caucasian (<italic>n</italic> = 13) and three were Asian in origin. The median duration of rheumatic disease before RTX treatment was nine years (range 0.2–27) and post-treatment follow-up time was 28 months (range 3 to 92). Ten patients (63%) were treated repeatedly with RTX either two (six patients), three (two patients) or four times (two patients) during the follow-up period. The indication for re-treatment was in seven patients thrombocytopenia flare, in two patients anti-phospholipid syndrome (APS) and one patient received RTX three times because of nephritis flare. The baseline characteristics of patients are shown in <xref ref-type="table" rid="table1-0961203313485489">Table 1</xref>.</p>
</sec>
<sec id="sec12-0961203313485489"><title>The clinical and immunological effects of RTX treatment</title>
<p>Complete depletion of B cells was achieved in 94% of cases one month after RTX treatment. In all but one patient there were no detectable CD19+ B cells in the circulation after the first RTX cycle. A significant increase (<italic>p</italic> = 0.0001) of platelet counts was seen already after one month (median 58 × 10<sup>9</sup>/ml vs. 110 × 10<sup>9</sup>/ml) (<xref ref-type="fig" rid="fig1-0961203313485489">Figure 1</xref>). Within three months after the first RTX cycle the platelet counts normalized in 10 patients (median 223 × 10<sup>9</sup>/ml), and in seven of them (44%) complete remission was achieved and maintained during the median follow-up period of 18 (range 3 to 86) months. However, in three of these patients RTX treatment was repeated because of SLE indications other than thrombocytopenia. In four out of 16 patients the treatment response following the first RTX treatment was transient with relapses in thrombocytopenia occurring within a median time of five (range three to eight) months. After the second RTX cycle three patients achieved complete remission that was maintained during the follow-up period of 6, 11 and 30 months, respectively. In one patient with partial response to the second treatment, a third RTX cycle was needed to induce 31 months’ remission. Three out of seven patients who received the second RTX cycle because of thrombocytopenia flare had measurable levels of CD19+ cells (5%, 3% and 6% in respective patients) in the peripheral blood; four patients displayed undetectable levels of B cells.
<fig id="fig1-0961203313485489" position="float"><label>Figure 1</label><caption><p>Platelet count before and following rituximab (RTX) treatment.</p>
<p>Box plots show the 25th and 75th percentiles. Horizontal black solid lines within boxes indicate medians, filled circles indicate means. Vertical bars indicate the fifth and 95th percentiles. *<italic>p</italic> &lt; 0.0005; <sup>§</sup><italic>p</italic> &lt; 0.005 as compared to levels before treatment.</p></caption><graphic xlink:href="10.1177_0961203313485489-fig1.tif"/>
</fig></p>
<p>Three patients (18%) did not respond to RTX treatment and their baseline median thrombocyte counts remained basically unchanged following one, three and six months of RTX treatment (60 × 10<sup>9</sup>/ml vs 75 × 10<sup>9</sup>/ml, 69 × 10<sup>9</sup>/ml and 65 × 10<sup>9</sup>/ml, respectively).</p>
<p>Antibodies of IgM and IgG isotypes were measured in 12 out of 16 patients before treatment, and seven patients had follow-up data. High levels (&gt;10% of platelets with autoantibodies bound to their surface) were detected in seven patients before RTX treatment (IgG; median 15%, range 5%–67%; IgM; median 11%, range 5%–46%). The autoantibody levels decreased significantly following RTX treatment (<xref ref-type="fig" rid="fig2-0961203313485489">Figure 2</xref>) and six patients achieved complete remission after treatment. Of note, these patients had also high titers of anti-thrombocyte antibodies. Nine patients had anti-double-stranded DNA (anti-dsDNA) antibodies before RTX treatment and a decrease was observed in eight patients within six months following RTX treatment.
<fig id="fig2-0961203313485489" position="float"><label>Figure 2</label><caption><p>Changes in anti-platelet antibodies following rituximab (RTX) treatment.</p>
<p>Box plots show the 25th and 75th percentiles. Horizontal black solid lines within boxes indicate medians, filled circles indicate means. Vertical bars indicate the 5th and 95th percentiles.</p></caption><graphic xlink:href="10.1177_0961203313485489-fig2.tif"/>
</fig></p>
<p>At RTX treatment initiation 88% of patients received oral corticosteroids. The median oral daily prednisolone dose decreased significantly (<italic>p</italic> &lt; 0.05) already one month after treatment as compared to baseline. The baseline prednisolone dose (median 22.5 (IQR 11–36) mg) was tapered to 10 (5–15) mg and 6.2 (5–10) mg within three and six months (<italic>p</italic> = 0.0056 and <italic>p</italic> = 0.0033), respectively.</p>
</sec>
<sec id="sec13-0961203313485489"><title>Safety aspects</title>
<p>RTX treatment was generally well tolerated. Twelve patients (75%) did not develop any severe allergic reactions or adverse effects after RTX infusions. Four patients discontinued treatment because of side effects. One patient developed osteitis/inflammation in the jaw probably originating from a deep tooth infection present before RTX treatment, and RTX treatment was stopped after the first infusion. Serum sickness symptoms with fever and rash developed in another patient after the second infusion during the first treatment cycle and the treatment was discontinued. However, 6.5 years later the patient received the second RTX cycle (four weekly infusions) without complications. During the third and fourth RTX cycle, only one weekly infusion was given. The treatment was also discontinued after two infusions during the second RTX cycle in the third patient because of the development of fever, rash and suspected allergic reaction. The development of leukopenia was seen in the fourth patient after the third infusion during the second RTX cycle. Three patients were lost for follow-up: Two patients moved after three and 18 months, respectively; the third patient died of dilated cardiomyopathy 18 months after RTX treatment.</p>
</sec>
</sec>
<sec id="sec14-0961203313485489"><title>Discussion and literature review</title>
<p>Approximately 7%–30% of patients with SLE will develop thrombocytopenia, and in up to 16% of patients it can predate the SLE diagnosis and be the initial disease manifestation.<sup><xref ref-type="bibr" rid="bibr9-0961203313485489">9</xref>,<xref ref-type="bibr" rid="bibr19-0961203313485489">19</xref></sup> In a recent retrospective study by Ziakas et al.,<sup><xref ref-type="bibr" rid="bibr8-0961203313485489">8</xref></sup> the prevalence of thrombocytopenia at the time of lupus diagnosis was found to be particularly high and was present in 58% of cases. Recent studies indicate that B cells participate in the pathogenesis of lupus and MCTD in several ways by producing polyclonal antibodies and cytokines and by supporting the activation of dendritic and T cells.<sup><xref ref-type="bibr" rid="bibr1-0961203313485489">1</xref></sup> Increased peripheral destruction of thrombocytes, associated with the presence of anti-thrombocyte antibodies on the surface of platelets, is the most likely pathogenetic mechanism.<sup><xref ref-type="bibr" rid="bibr20-0961203313485489">20</xref></sup> The central role for B lymphocytes in the pathogenesis of these autoimmune diseases provides a rationale for the use of B-cell depletion with RTX, a chimeric anti-CD20 monoclonal antibody. RTX attacks B cells by several mechanisms, including antibody-dependent cellular cytotoxicity, complement-dependent destruction of B cells as well as apoptosis induction.<sup><xref ref-type="bibr" rid="bibr21-0961203313485489">21</xref>,<xref ref-type="bibr" rid="bibr22-0961203313485489">22</xref></sup></p>
<p>To date, RTX has been used in SLE patients as an off-label rescue medication in cases of different severe disease manifestations, including AITP refractory to conventional treatment with corticosteroids, IVIG and disease-modifying anti-rheumatic drugs (DMARDs).<sup><xref ref-type="bibr" rid="bibr23-0961203313485489">23</xref>,<xref ref-type="bibr" rid="bibr24-0961203313485489">24</xref></sup> There is great previously reviewed and published evidence regarding the outcome of RTX treatment of SLE.<sup><xref ref-type="bibr" rid="bibr24-0961203313485489">24</xref><xref ref-type="bibr" rid="bibr25-0961203313485489"/>–<xref ref-type="bibr" rid="bibr26-0961203313485489">26</xref></sup> Also, two randomized clinical trials investigating B cell depletion in non-renal<sup><xref ref-type="bibr" rid="bibr27-0961203313485489">27</xref></sup> and renal<sup><xref ref-type="bibr" rid="bibr28-0961203313485489">28</xref></sup> SLE have been conducted but generated conflicting results and failed to meet their primary endpoints, probably attributable to study design and the heterogeneity of the SLE cohorts. In these trials and reviews, however, the outcome of RTX specifically in SLE-related thrombocytopenias has not been addressed. In this study, we have evaluated the outcome of RTX-treated SLE and MCTD patients with thrombocytopenia and reviewed the available published literature in this regard.</p>
<p>We performed a comprehensive PubMed search to identify all English-language articles through December 2011 that documented RTX in the treatment of SLE- and MCTD-related AITP and thrombotic thrombocytopenia (TTP). The following combinations of Medical Subject Heading (MeSH) terms were used: MCTD and RTX, SLE and RTX and thrombocytopenia; SLE and RTX. Articles describing the effect of RTX treatment in children with SLE-related thrombocytopenia, cases with primary idiopathic (not SLE-/MCTD-related) ITP/TTP as well as primary antiphospholipid antibody syndrome have been reviewed elsewhere<sup><xref ref-type="bibr" rid="bibr26-0961203313485489">26</xref>,<xref ref-type="bibr" rid="bibr29-0961203313485489">29</xref><xref ref-type="bibr" rid="bibr30-0961203313485489"/>–<xref ref-type="bibr" rid="bibr31-0961203313485489">31</xref></sup> and were not included. All case falls were identified and patients with thrombocytopenia from larger SLE cohorts treated with RTX were extracted for analysis, if possible. References and review articles were searched for unique cases.</p>
<p>The first successful case of RTX therapy in the treatment of SLE and AITP was described in 2002 by Kneitz et al.<sup><xref ref-type="bibr" rid="bibr32-0961203313485489">32</xref></sup> During the last decade published evidence on off-label RTX treatment in SLE-associated thrombocytopenia has increased and suggests a favorable effect. Our search yielded 24 articles including 18 case reports, one retrospective cohort study and five prospective studies documenting 65 patients.<sup><xref ref-type="bibr" rid="bibr18-0961203313485489">18</xref>,<xref ref-type="bibr" rid="bibr32-0961203313485489">32</xref><xref ref-type="bibr" rid="bibr33-0961203313485489"/><xref ref-type="bibr" rid="bibr34-0961203313485489"/><xref ref-type="bibr" rid="bibr35-0961203313485489"/><xref ref-type="bibr" rid="bibr36-0961203313485489"/><xref ref-type="bibr" rid="bibr37-0961203313485489"/><xref ref-type="bibr" rid="bibr38-0961203313485489"/><xref ref-type="bibr" rid="bibr39-0961203313485489"/><xref ref-type="bibr" rid="bibr40-0961203313485489"/><xref ref-type="bibr" rid="bibr41-0961203313485489"/><xref ref-type="bibr" rid="bibr42-0961203313485489"/><xref ref-type="bibr" rid="bibr43-0961203313485489"/><xref ref-type="bibr" rid="bibr44-0961203313485489"/><xref ref-type="bibr" rid="bibr45-0961203313485489"/><xref ref-type="bibr" rid="bibr46-0961203313485489"/><xref ref-type="bibr" rid="bibr47-0961203313485489"/><xref ref-type="bibr" rid="bibr48-0961203313485489"/><xref ref-type="bibr" rid="bibr49-0961203313485489"/><xref ref-type="bibr" rid="bibr50-0961203313485489"/><xref ref-type="bibr" rid="bibr51-0961203313485489"/><xref ref-type="bibr" rid="bibr52-0961203313485489"/><xref ref-type="bibr" rid="bibr53-0961203313485489"/><xref ref-type="bibr" rid="bibr54-0961203313485489"/>–<xref ref-type="bibr" rid="bibr55-0961203313485489">55</xref></sup> Fifty-five patients received RTX because of immune thrombocytopenia and in 10 patients TTP was diagnosed. The results are summarized in <xref ref-type="table" rid="table2-0961203313485489">Table 2</xref>. Only few cases have been published regarding the use of RTX in the treatment of MCTD-related thrombocytopenia.<sup><xref ref-type="bibr" rid="bibr17-0961203313485489">17</xref>,<xref ref-type="bibr" rid="bibr39-0961203313485489">39</xref>,<xref ref-type="bibr" rid="bibr49-0961203313485489">49</xref></sup> Fifty-one patients out of 65 (78%) reviewed here (<xref ref-type="table" rid="table2-0961203313485489">Table 2</xref>) achieved complete and six patients (9%) partial response within a median time to response of four (range one to 24) weeks and a median follow-up time of 12.5 (two to 60) months. There was no improvement regarding thrombocytopenia in three cases (4.6%), and three patients (4.6%) died. Relapses occurred in five out of 38 (13%) patients within a median time of nine (range 9 to 24) months.
<table-wrap id="table2-0961203313485489" position="float"><label>Table 2</label><caption><p>Previous reports on the use of rituximab (RTX) in thrombocytopenia related to SLE and/or connective-tissue diseases</p></caption>
<graphic alternate-form-of="table2-0961203313485489" xlink:href="10.1177_0961203313485489-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>First author</th>
<th>Year</th>
<th>Platelet- associated anti-bodies</th>
<th>Study</th>
<th>Indication (diagnosis)</th>
<th>Patient no</th>
<th>Previous treatment that failed</th>
<th>RTX dose</th>
<th>Response regarding ITP</th>
<th>Time to response/ remission (weeks) (w)</th>
<th>Follow-up (month) (m)</th>
<th>Relapses during follow-up</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Kneitz<sup><xref ref-type="bibr" rid="bibr32-0961203313485489">32</xref></sup></td>
<td>2002</td>
<td>Positive → no change</td>
<td>Case report</td>
<td>1– AITP (SLE) 2 –A ITP, nephritis</td>
<td>2<sup>b</sup></td>
<td>1) CS, splenectomy 2) CS, CYC, AZA,  MMF,</td>
<td>375 mg/m<sup>2</sup>/week × 4 infusions</td>
<td>1 – CR 2 – PR</td>
<td>12 w —</td>
<td>30 m —</td>
<td>No —</td>
</tr>
<tr>
<td>Tomietto<sup><xref ref-type="bibr" rid="bibr34-0961203313485489">34</xref></sup></td>
<td>2004</td>
<td>Positive →negative</td>
<td>Case report</td>
<td>AITP, AIHA, CNS (SLE)</td>
<td>1</td>
<td>CS, CYA,  IVIG, MMF, AZA</td>
<td>375 mg/m<sup>2</sup>/week × 4 infusions</td>
<td>1 – CR</td>
<td>2 w</td>
<td>16 m</td>
<td>12 m</td>
</tr>
<tr>
<td>Van den Bergh<sup><xref ref-type="bibr" rid="bibr35-0961203313485489">35</xref></sup></td>
<td>2005</td>
<td>Case report</td>
<td>AITP, AIHA, nephritis, pneumonitis, (SLE/SS overlap)</td>
<td>1</td>
<td>CS, CYC, IVIG, plasmaferesis</td>
<td>375 mg/m<sup>2</sup>/week × 4 infusions</td>
<td>CR</td>
<td>4 w</td>
<td>12 m</td>
<td>No</td>
</tr>
<tr>
<td>Ahn<sup><xref ref-type="bibr" rid="bibr36-0961203313485489">36</xref></sup></td>
<td>2005</td>
<td>Case report</td>
<td>AITP, (SLE, severe APS)</td>
<td>1</td>
<td>CYC, plasmaferesis</td>
<td>375 mg/m<sup>2</sup>/week × 4 infusions</td>
<td>CR</td>
<td>7 w</td>
<td>15 m</td>
<td>No</td>
</tr>
<tr>
<td>Paran<sup><xref ref-type="bibr" rid="bibr37-0961203313485489">37</xref></sup></td>
<td>2006</td>
<td>Case report</td>
<td>AITP, nephritis, (SLE)</td>
<td>1</td>
<td>CS, CYC, IVIG</td>
<td>375 mg/m<sup>2</sup>/week × 4 infusions</td>
<td>CR</td>
<td>rapid</td>
<td>No</td>
</tr>
<tr>
<td>Anandacoomarasamy<sup><xref ref-type="bibr" rid="bibr38-0961203313485489">38</xref></sup></td>
<td>2006</td>
<td>Positive → NA</td>
<td>Case report</td>
<td>AITP, (SLE, severe APS)</td>
<td>1</td>
<td>CS, CYC, IVIG,  CYA, VCR, DPS</td>
<td>375 mg/m<sup>2</sup>/week × 4 infusions</td>
<td>CR</td>
<td>ca 6 w</td>
<td>30 m</td>
<td>No</td>
</tr>
<tr>
<td>Niewold<sup><xref ref-type="bibr" rid="bibr39-0961203313485489">39</xref></sup></td>
<td>2006</td>
<td>Case report</td>
<td>1 – TTP (SLE) 2 – TTP (overlap CTD)</td>
<td>2</td>
<td>1) CS, plasma  exchange 2) CS, plasma  exchange, hemodialysis</td>
<td>375 mg/m<sup>2</sup>/week × 2 and 4 infusions,  respectively</td>
<td>CR</td>
<td>1 w</td>
<td>2 m</td>
<td>No</td>
</tr>
<tr>
<td>Ng<sup><xref ref-type="bibr" rid="bibr40-0961203313485489">40</xref></sup></td>
<td>2007</td>
<td>Open prospective study (32 pat)</td>
<td>2 – AITP (SLE) 1 – AITP, nephritis,  AIHA, (SLE)</td>
<td>3</td>
<td>1) CS, HCQ 2) CS, HCQ,AZA 3) CS, HCQ,  CYC, AZA,  MMF, IVIG</td>
<td>1000 mg / 2 weeks ×  2 infusions</td>
<td>CR</td>
<td>9, 47, 60 m</td>
<td>No</td>
</tr>
<tr>
<td>Limal<sup><xref ref-type="bibr" rid="bibr41-0961203313485489">41</xref></sup></td>
<td>2007</td>
<td>Case report</td>
<td>TTP (SLE, APS)</td>
<td>1</td>
<td>CS, AZA,  HCQ,  plasma exchange</td>
<td>375 mg/m<sup>2</sup>/week × 4 infusions</td>
<td>CR</td>
<td>1 w</td>
<td>15 m</td>
<td>No</td>
</tr>
<tr>
<td>Fukushima<sup><xref ref-type="bibr" rid="bibr42-0961203313485489">42</xref></sup></td>
<td>2008</td>
<td>IgG decrease</td>
<td>Case report</td>
<td>AMT, CNS, serositis,  nephritis, (SLE)</td>
<td>1</td>
<td>CS, CYA</td>
<td>375 mg/m<sup>2</sup>/week × 2 infusions</td>
<td>CR</td>
<td>2.5 m</td>
<td>8 m</td>
<td>No</td>
</tr>
<tr>
<td>Kittaka<sup><xref ref-type="bibr" rid="bibr43-0961203313485489">43</xref></sup></td>
<td>2008</td>
<td>IgG decrease</td>
<td>Case report</td>
<td>AIHA, AITP, (SLE)</td>
<td>1</td>
<td>CS, CYA, IVIG,  splenectomy</td>
<td>375 mg/m<sup>2</sup>/week × 2 infusions</td>
<td>CR</td>
<td>4 w</td>
<td>6 m</td>
<td>No</td>
</tr>
<tr>
<td>Hundae<sup><xref ref-type="bibr" rid="bibr33-0961203313485489">33</xref></sup></td>
<td>2008</td>
<td>Case report</td>
<td>TTP, nephritis, (SLE)</td>
<td>1</td>
<td>CS, HCQ, plasma  exchange</td>
<td>2 courses</td>
<td>CR</td>
<td>No</td>
</tr>
<tr>
<td>Nadri<sup><xref ref-type="bibr" rid="bibr44-0961203313485489">44</xref></sup></td>
<td>2009</td>
<td>Case report</td>
<td>AITP, ESRD (SLE)</td>
<td>1</td>
<td>CS, CYC, IVIG,  MMF, CYA, dialysis, plasma  exchange</td>
<td>375 mg/m<sup>2</sup>/week × 4 infusions</td>
<td>CR</td>
<td>4 w</td>
<td>No</td>
</tr>
<tr>
<td>Reis<sup><xref ref-type="bibr" rid="bibr45-0961203313485489">45</xref></sup></td>
<td>2009</td>
<td>Case report</td>
<td>AITP (SLE)</td>
<td>2<sup>b</sup></td>
<td>1) CS, AZA 2) CS, AZA, IVIG,  DAZ</td>
<td>375 mg/m<sup>2</sup>/week × 4 infusions</td>
<td>CR CR</td>
<td>17 m 9 m</td>
<td>No 9 m</td>
</tr>
<tr>
<td>Mardjuardi<sup><xref ref-type="bibr" rid="bibr46-0961203313485489">46</xref></sup></td>
<td>2009</td>
<td>Case report</td>
<td>AITP, nephritis, (SLE)</td>
<td>1</td>
<td>CS, MMF</td>
<td>500 mg / 2 weeks × 3 infusions</td>
<td>CR</td>
<td>2 w</td>
<td>7 m</td>
<td>No</td>
</tr>
<tr>
<td>Letchumanan<sup><xref ref-type="bibr" rid="bibr47-0961203313485489">47</xref></sup></td>
<td>2009</td>
<td>Cohort study</td>
<td>TTP (SLE)</td>
<td>3<sup>b</sup></td>
<td>Plasmaferesis, CS (3),  MMF (3), CYC (1)</td>
<td>375 mg/m<sup>2</sup>/week × 1, 4 and 11 infusions</td>
<td>2 – Died 1 – CR</td>
<td>3 w</td>
</tr>
<tr>
<td>Lateef<sup><xref ref-type="bibr" rid="bibr48-0961203313485489">48</xref></sup></td>
<td>2010</td>
<td>Retrospective cohort <bold>(10 pat)</bold></td>
<td>AITP (SLE)</td>
<td>3<sup>b</sup></td>
<td>CS (3), MMF (3),  CYC(2), HCQ (3),  CYA(3), AZA (2), IVIG (1)</td>
<td>375 mg/m<sup>2</sup>/ 2 weeks</td>
<td>2 – CR 1 –PR</td>
<td>median 18 m</td>
<td>2 – no 1 – 24 m</td>
</tr>
<tr>
<td>Zheng<sup><xref ref-type="bibr" rid="bibr49-0961203313485489">49</xref></sup></td>
<td>2009</td>
<td>Case report</td>
<td>AITP (3 SLE, 1 CTD)</td>
<td>4<sup>b</sup></td>
<td>CS (4), CYC(3),  IVIG (3), VCR (3), CYA (2),  splenectomy (2)</td>
<td>375 mg/m<sup>2</sup>/week × 3–4 infusions</td>
<td>3 – CR 1 – Death</td>
<td>1-4 w</td>
<td>6, 13, 35 m</td>
<td>No</td>
</tr>
<tr>
<td>Lee<sup><xref ref-type="bibr" rid="bibr50-0961203313485489">50</xref></sup></td>
<td>2010</td>
<td>Positive → NA</td>
<td>Case report</td>
<td>TTP (SLE)</td>
<td>1</td>
<td>CS, plasmaferesis</td>
<td>375 mg/m<sup>2</sup>/week × 3 infusions</td>
<td>CR</td>
<td>2 w</td>
<td>10 m</td>
<td>No</td>
</tr>
<tr>
<td>Terrier<sup><xref ref-type="bibr" rid="bibr51-0961203313485489">51</xref></sup></td>
<td>2010</td>
<td>Prospective multi-center  registry analysis <bold>(136 pat)</bold></td>
<td>AITP (SLE)</td>
<td>13<sup>b</sup></td>
<td>Various<sup>a</sup></td>
<td>1000 mg / 2 weeks × 2 infusions or 375 mg/m<sup>2</sup>/week × 4 infusions</td>
<td>CR – 10 PR – 2 NR - 1</td>
<td>mean 6 ± 3 m</td>
</tr>
<tr>
<td>Niaz<sup><xref ref-type="bibr" rid="bibr52-0961203313485489">52</xref></sup></td>
<td>2010</td>
<td>Case report</td>
<td>TTP (SLE)</td>
<td>1</td>
<td>CS, plasma exchange</td>
<td>375 mg/m<sup>2</sup>/week × 3 infusions</td>
<td>CR</td>
<td>2 w</td>
<td>8 m</td>
<td>No</td>
</tr>
<tr>
<td>García-Carrasco<sup><xref ref-type="bibr" rid="bibr53-0961203313485489">53</xref></sup></td>
<td>2010</td>
<td>Prospective single-center <bold>(52 pat)</bold></td>
<td>AITP (SLE)</td>
<td>8<sup>b</sup></td>
<td>Various <sup>a</sup></td>
<td>1000 mg / 2 weeks  × 2 infusions</td>
<td>1 – AE 6/7 - CR</td>
<td>mean 12 w</td>
<td>6 m</td>
<td>6/7 - No</td>
</tr>
<tr>
<td>Chen<sup><xref ref-type="bibr" rid="bibr18-0961203313485489">18</xref></sup></td>
<td>2011</td>
<td>Prospective pilot study <bold>(10 pat)</bold></td>
<td>AITP (SLE)</td>
<td>10</td>
<td>CS, CYC,  IVIG, CSA, VCR; splenectomy (1)</td>
<td>100 mg /week × 4 infusions</td>
<td>6 – CR 2 – PR 2 – No</td>
<td>2–4 w 4–12 w 2–24 w</td>
<td>8.5 m</td>
<td>4 – No 2 – w 36</td>
</tr>
<tr>
<td>Gupta<sup><xref ref-type="bibr" rid="bibr54-0961203313485489">54</xref></sup></td>
<td>2011</td>
<td>Case report</td>
<td>AITP, PRCA (SLE)</td>
<td>1</td>
<td>CS, IVIG, CYC</td>
<td>1000 mg /10 days  × 2 infusions + 1 dose to reach 375 mg/m<sup>2</sup>/ 4 weeks</td>
<td>CR</td>
<td>4 w</td>
<td>7 m</td>
<td>No</td>
</tr>
<tr>
<td>Pinto <sup><xref ref-type="bibr" rid="bibr55-0961203313485489">55</xref></sup></td>
<td>2011</td>
<td>Prospective observational  cohort <bold>(42 pat)</bold></td>
<td>AITP (SLE)</td>
<td>1<sup>b</sup></td>
<td>1000 mg / 2 weeks × 2 infusions</td>
<td>CR</td>
<td>12 w</td>
<td>21 m</td>
<td>No</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203313485489"><p>SLE: systemic lupus erythematosus; CNS: central nervous system; VCR: vincristine; DAZ: danazol; CYC: cyclophosphamide; CS: corticosteroids; AZA: azathioprine: IVIG: intravenous immunoglobulin; CSA: cyclosporine; MMF: mycophenolate mofetil; DPS: dapsone; SS: systemic sclerosis; CTD: connective-tissue disease; TTP: thrombotic thrombocytopenic purpura; AMT: amegacaryocytic thrombocytopenia; AITP: autoimmune thrombocytopenia; AIHA: autoimmune hemolytic anemia; PRCA: pure red cell aplasia; NA: not analyzed; CR: complete remission; PR: partial remission; NR: no remission; AE: adverse effects.<sup>a</sup>Larger SLE patient cohorts analyzed and specific treatment was not indicated for AITP patients. <sup>b</sup>Only SLE patients with thrombocytopenia were included in the table from larger study cohorts.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>In corroboration with these results, in our study cohort the overall response rate to RTX was 81%, of whom 11 patients (69%) displayed complete and two patients (12.5%) partial treatment response regarding thrombocytopenia. In addition, seven patients (44%) achieved complete long-term remission regarding thrombocytopenia after the first RTX cycle; six of 16 patients (37.5%) had a relapse within a period of three to nine months and positively responded to one (<italic>n</italic> = 3) or two (<italic>n</italic> = 2) re-treatments with RTX. In one patient, only partial response was achieved and three patients (18.5%) did not respond, whereas one patient (6%) died. Our study showed that relapses occurred during the first nine months, and one to two re-treatments were sufficient to introduce patients to long-term remission.</p>
<p>In addition to reviewed cases, Tew et al. recently reported analyzing data from the randomized, double-blind, placebo-controlled Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial that platelet levels normalized in a subgroup of 16 RTX-treated patients who entered the study with low baseline counts.<sup><xref ref-type="bibr" rid="bibr56-0961203313485489">56</xref></sup> Unfortunately, these patients were not further analyzed in detail. Also, two prospective studies reported by Terrier et al.<sup><xref ref-type="bibr" rid="bibr51-0961203313485489">51</xref></sup> and García-Carrasco et al.<sup><xref ref-type="bibr" rid="bibr53-0961203313485489">53</xref></sup> with 13 and eight patients out of 136 and 52, respectively, showed that thrombocytopenia responded to RTX in 85% of cases. These results diminish the publication bias that otherwise would be obvious while analyzing data from case falls.</p>
<p>We observed that patients with high detectable levels of anti-platelet antibodies responded better to RTX therapy than patients without antibodies. This is in line with several other, albeit few, studies in which the levels of anti-platelet antibodies were analyzed<sup><xref ref-type="bibr" rid="bibr32-0961203313485489">32</xref>,<xref ref-type="bibr" rid="bibr34-0961203313485489">34</xref>,<xref ref-type="bibr" rid="bibr38-0961203313485489">38</xref>,<xref ref-type="bibr" rid="bibr42-0961203313485489">42</xref>,<xref ref-type="bibr" rid="bibr43-0961203313485489">43</xref>,<xref ref-type="bibr" rid="bibr50-0961203313485489">50</xref></sup> (<xref ref-type="table" rid="table2-0961203313485489">Table 2</xref>). In six SLE patients anti-platelet antibodies were identified and five of them (83%) had no flare whereas one relapsed after 12 months. Thrombocytopenia as a manifestation of APS in patients with SLE is frequently related to the presence of antiphospholipid antibodies, and in these patients as well RTX has shown to have a beneficial effect.<sup><xref ref-type="bibr" rid="bibr26-0961203313485489">26</xref>,<xref ref-type="bibr" rid="bibr57-0961203313485489">57</xref></sup> This finding is consistent with the favorable effect of RTX treatment in patients with primary ITP<sup><xref ref-type="bibr" rid="bibr29-0961203313485489">29</xref>,<xref ref-type="bibr" rid="bibr30-0961203313485489">30</xref></sup> and supports a pathogenetic role for autoantibodies in platelet destruction.</p>
<p>In most published studies RTX has been given intravenously once weekly during four consecutive weeks at the dosage of 375 mg/m<sup>2</sup>, and in some studies a schedule used for rheumatoid arthritis with 1000 mg twice biweekly has been administered. However, in a recent prospective study by Chen et al.,<sup><xref ref-type="bibr" rid="bibr18-0961203313485489">18</xref></sup> RTX at a low dose of 100 mg once weekly for four weeks was shown to induce a complete response in 60% of SLE patients with severe refractory thrombocytopenia at week 12.</p>
<p>In conclusion, current evidence indicates that RTX therapy is efficacious in approximately 80% of patients with AITP secondary to SLE/MCTD whose conditions had failed previous immunosuppressive therapies. Best response may be expected in patients with high titers of anti-platelet antibodies, and RTX can induce long-term complete remission in these patients. We believe that these results warrant further prospective trials to confirm the safety and efficacy of RTX in severe ITP secondary to SLE and/or MCTD.</p>
</sec>
</body>
<back>
<sec id="sec15-0961203313485489"><title>Funding</title>
<p>This work was supported by grants from the Gothenburg Medical Society, the Swedish Medical Society, the Swedish Association against Rheumatism, the Gothenburg Association against Rheumatism, the Rune and Ulla Almlövs Foundation, the Family Thölens and Kristlers Foundation, the Nanna Svartz Foundation, and the University of Gothenburg.</p>
</sec>
<sec id="sec16-0961203313485489"><title>Conflict of interest</title>
<p>None declared.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313485489"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorner</surname><given-names>T</given-names></name><name><surname>Giesecke</surname><given-names>C</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name></person-group>. <article-title>Mechanisms of B cell autoimmunity in SLE</article-title>. <source>Arthritis Res Ther</source> <year>2011</year>; <volume>13</volume>: <fpage>243</fpage>–<lpage>243</lpage>.</citation></ref>
<ref id="bibr2-0961203313485489"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>F</given-names></name><name><surname>Chan</surname><given-names>AC</given-names></name></person-group>. <article-title>B cell immunobiology in disease: Evolving concepts from the clinic</article-title>. <source>Annu Rev Immunol</source> <year>2006</year>; <volume>24</volume>: <fpage>467</fpage>–<lpage>496</lpage>.</citation></ref>
<ref id="bibr3-0961203313485489"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>RW</given-names></name><name><surname>Maldonado</surname><given-names>ME</given-names></name></person-group>. <article-title>Immune pathogenesis of mixed connective tissue disease: A short analytical review</article-title>. <source>Clin Immunol</source> <year>2008</year>; <volume>128</volume>: <fpage>8</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr4-0961203313485489"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Benseler</surname><given-names>SM</given-names></name><name><surname>Kirby-Allen</surname><given-names>M</given-names></name><name><surname>Silverman</surname><given-names>ED</given-names></name></person-group>. <article-title>B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus</article-title>. <source>Pediatrics</source> <year>2009</year>; <volume>123</volume>: <fpage>e159</fpage>–<lpage>e163</lpage>.</citation></ref>
<ref id="bibr5-0961203313485489"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sultan</surname><given-names>SM</given-names></name><name><surname>Begum</surname><given-names>S</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems</article-title>. <source>Rheumatology (Oxford)</source> <year>2003</year>; <volume>42</volume>: <fpage>230</fpage>–<lpage>234</lpage>.</citation></ref>
<ref id="bibr6-0961203313485489"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nossent</surname><given-names>JC</given-names></name><name><surname>Swaak</surname><given-names>AJ</given-names></name></person-group>. <article-title>Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus</article-title>. <source>Q J Med</source> <year>1991</year>; <volume>80</volume>: <fpage>605</fpage>–<lpage>612</lpage>.</citation></ref>
<ref id="bibr7-0961203313485489"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Ho</surname><given-names>CT</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name><name><surname>Wong</surname><given-names>RW</given-names></name></person-group>. <article-title>A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population</article-title>. <source>Rheumatology (Oxford)</source> <year>2000</year>; <volume>39</volume>: <fpage>399</fpage>–<lpage>406</lpage>.</citation></ref>
<ref id="bibr8-0961203313485489"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ziakas</surname><given-names>PD</given-names></name><name><surname>Giannouli</surname><given-names>S</given-names></name><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Tzioufas</surname><given-names>AG</given-names></name><name><surname>Voulgarelis</surname><given-names>M</given-names></name></person-group>. <article-title>Lupus thrombocytopenia: Clinical implications and prognostic significance</article-title>. <source>Ann Rheum Dis</source> <year>2005</year>; <volume>64</volume>: <fpage>1366</fpage>–<lpage>1369</lpage>.</citation></ref>
<ref id="bibr9-0961203313485489"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hepburn</surname><given-names>AL</given-names></name><name><surname>Narat</surname><given-names>S</given-names></name><name><surname>Mason</surname><given-names>JC</given-names></name></person-group>. <article-title>The management of peripheral blood cytopenias in systemic lupus erythematosus</article-title>. <source>Rheumatology (Oxford)</source> <year>2010</year>; <volume>49</volume>: <fpage>2243</fpage>–<lpage>2254</lpage>.</citation></ref>
<ref id="bibr10-0961203313485489"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zandman‐Goddard</surname><given-names>G</given-names></name><name><surname>Levy</surname><given-names>Y</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Intravenous immunoglobulin therapy and systemic lupus erythematosus</article-title>. <source>Clin Rev Allergy Immunol</source> <year>2005</year>; <volume>29</volume>: <fpage>219</fpage>–<lpage>228</lpage>.</citation></ref>
<ref id="bibr11-0961203313485489"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>HR</given-names></name><name><surname>Steinberg</surname><given-names>AD</given-names></name></person-group>. <article-title>Autoimmunity—a perspective</article-title>. <source>Annu Rev Immunol</source> <year>1983</year>; <volume>1</volume>: <fpage>175</fpage>–<lpage>210</lpage>.</citation></ref>
<ref id="bibr12-0961203313485489"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnal</surname><given-names>C</given-names></name><name><surname>Piette</surname><given-names>JC</given-names></name><name><surname>Léone</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases</article-title>. <source>J Rheumatol</source> <year>2002</year>; <volume>29</volume>: <fpage>75</fpage>–<lpage>83</lpage>.</citation></ref>
<ref id="bibr13-0961203313485489"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>N</given-names></name><name><surname>Stasi</surname><given-names>R</given-names></name><name><surname>Cunningham-Rundles</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura</article-title>. <source>Br J Haematol</source> <year>2004</year>; <volume>125</volume>: <fpage>232</fpage>–<lpage>239</lpage>.</citation></ref>
<ref id="bibr14-0961203313485489"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>AS</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>The 1982 revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>1271</fpage>–<lpage>1277</lpage>.</citation></ref>
<ref id="bibr15-0961203313485489"><label>15</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kasukawa</surname><given-names>R</given-names></name><name><surname>Tojo</surname><given-names>T</given-names></name><name><surname>Miyawaki</surname><given-names>S</given-names></name></person-group> <article-title>Preliminary diagnostic criteria for classification of mixed connective tissue disease</article-title>. In: <person-group person-group-type="editor"><name><surname>Kasukawa</surname><given-names>R</given-names></name><name><surname>Sharp</surname><given-names>GC</given-names></name></person-group> (eds). <source>Mixed connective tissue disease and antinuclear antibodies</source>, <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <year>1987</year>, pp. <fpage>41</fpage>–<lpage>47</lpage>.</citation></ref>
<ref id="bibr16-0961203313485489"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alarcón-Segovia</surname><given-names>D</given-names></name><name><surname>Cardiel</surname><given-names>MH</given-names></name></person-group>. <article-title>Comparison between 3 diagnostic criteria for mixed connective tissue disease</article-title>. <source>Study of 593 patients. <italic>J Rheumatol</italic></source> <year>1989</year>; <volume>16</volume>: <fpage>328</fpage>–<lpage>334</lpage>.</citation></ref>
<ref id="bibr17-0961203313485489"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindholm</surname><given-names>C</given-names></name><name><surname>Börjesson-Asp</surname><given-names>K</given-names></name><name><surname>Zendjanchi</surname><given-names>K</given-names></name><name><surname>Sundqvist</surname><given-names>AC</given-names></name><name><surname>Tarkowski</surname><given-names>A</given-names></name><name><surname>Bokarewa</surname><given-names>M</given-names></name></person-group>. <article-title>Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2008</year>; <volume>35</volume>: <fpage>826</fpage>–<lpage>833</lpage>.</citation></ref>
<ref id="bibr18-0961203313485489"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus—a prospective pilot study</article-title>. <source>Rheumatology (Oxford)</source> <year>2011</year>; <volume>50</volume>: <fpage>1640</fpage>–<lpage>1644</lpage>.</citation></ref>
<ref id="bibr19-0961203313485489"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mestanza-Peralta</surname><given-names>M</given-names></name><name><surname>Ariza-Ariza</surname><given-names>R</given-names></name><name><surname>Cardiel</surname><given-names>MH</given-names></name><name><surname>Alcocer-Varela</surname><given-names>J</given-names></name></person-group>. <article-title>Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1997</year>; <volume>24</volume>: <fpage>867</fpage>–<lpage>870</lpage>.</citation></ref>
<ref id="bibr20-0961203313485489"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Piette</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Platelet autoantibodies and lupus-associated thrombocytopenia</article-title>. <source>Br J Haematol</source> <year>2002</year>; <volume>119</volume>: <fpage>354</fpage>–<lpage>358</lpage>.</citation></ref>
<ref id="bibr21-0961203313485489"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorner</surname><given-names>T</given-names></name></person-group>. <article-title>Crossroads of B cell activation in autoimmunity: Rationale of targeting B cells</article-title>. <source>J Rheumatol Suppl</source> <year>2006</year>; <volume>77</volume>: <fpage>3</fpage>–<lpage>11</lpage>.</citation></ref>
<ref id="bibr22-0961203313485489"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>MY</given-names></name></person-group>. <article-title>The immunological basis of B-cell therapy in systemic lupus erythematosus</article-title>. <source>Int J Rheum Dis</source> <year>2010</year>; <volume>13</volume>: <fpage>3</fpage>–<lpage>11</lpage>.</citation></ref>
<ref id="bibr23-0961203313485489"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Brito-Zerón</surname><given-names>P</given-names></name><name><surname>Muñoz</surname><given-names>S</given-names></name><name><surname>Soto</surname><given-names>MJ</given-names></name></person-group>. <collab>BIOGEAS Study Group</collab>. <article-title>A systematic review of the off-label use of biological therapies in systemic autoimmune diseases</article-title>. <source>Medicine (Baltimore)</source> <year>2008</year>; <volume>87</volume>: <fpage>345</fpage>–<lpage>364</lpage>.</citation></ref>
<ref id="bibr24-0961203313485489"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gürcan</surname><given-names>HM</given-names></name><name><surname>Keskin</surname><given-names>DB</given-names></name><name><surname>Stern</surname><given-names>JN</given-names></name><name><surname>Nitzberg</surname><given-names>MA</given-names></name><name><surname>Shekhani</surname><given-names>H</given-names></name><name><surname>Ahmed</surname><given-names>AR</given-names></name></person-group>. <article-title>A review of the current use of rituximab in autoimmune diseases</article-title>. <source>Int Immunopharmacol</source> <year>2009</year>; <volume>9</volume>: <fpage>10</fpage>–<lpage>25</lpage>.</citation></ref>
<ref id="bibr25-0961203313485489"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Favas</surname><given-names>C</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>B-cell-depletion therapy in SLE—what are the current prospects for its acceptance?</article-title> <source>Nat Rev Rheumatol</source> <year>2009</year>; <volume>5</volume>: <fpage>711</fpage>–<lpage>716</lpage>.</citation></ref>
<ref id="bibr26-0961203313485489"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>García-Carrasco</surname><given-names>M</given-names></name><name><surname>Jiménez-Hernández</surname><given-names>M</given-names></name><name><surname>Escárcega</surname><given-names>RO</given-names></name><etal/></person-group>. <article-title>Use of rituximab in patients with systemic lupus erythematosus: An update</article-title>. <source>Autoimmun Rev</source> <year>2009</year>; <volume>8</volume>: <fpage>343</fpage>–<lpage>348</lpage>.</citation></ref>
<ref id="bibr27-0961203313485489"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>JT</given-names></name><name><surname>Neuwelt</surname><given-names>CM</given-names></name><name><surname>Wallace</surname><given-names>DJ</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial</article-title>. <source>Arthritis Rheum</source> <year>2010</year>; <volume>62</volume>: <fpage>222</fpage>–<lpage>233</lpage>.</citation></ref>
<ref id="bibr28-0961203313485489"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rovin</surname><given-names>BH</given-names></name><name><surname>Furie</surname><given-names>R</given-names></name><name><surname>Latinis</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study</article-title>. <source>Arthritis Rheum</source> <year>2012</year>; <volume>64</volume>: <fpage>1215</fpage>–<lpage>1226</lpage>.</citation></ref>
<ref id="bibr29-0961203313485489"><label>29</label><citation citation-type="other"><comment>Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: A meta-analysis. <italic>Br J Haematol</italic> 2012: 386–398</comment>.</citation></ref>
<ref id="bibr30-0961203313485489"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tun</surname><given-names>NM</given-names></name><name><surname>Villani</surname><given-names>GM</given-names></name></person-group>. <article-title>Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: A systematic review with pooled data analysis</article-title>. <source>J Thromb Thrombolysis</source> <year>2012</year>; <volume>34</volume>: <fpage>347</fpage>–<lpage>359</lpage>.</citation></ref>
<ref id="bibr31-0961203313485489"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Roubey</surname><given-names>RA</given-names></name></person-group>. <article-title>Use of rituximab in the antiphospholipid syndrome</article-title>. <source>Curr Rheumatol Rep</source> <year>2010</year>; <volume>12</volume>: <fpage>40</fpage>–<lpage>44</lpage>.</citation></ref>
<ref id="bibr32-0961203313485489"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kneitz</surname><given-names>C</given-names></name><name><surname>Wilhelm</surname><given-names>M</given-names></name><name><surname>Tony</surname><given-names>HP</given-names></name></person-group>. <article-title>Effective B cell depletion with rituximab in the treatment of autoimmune diseases</article-title>. <source>Immunobiology</source> <year>2002</year>; <volume>206</volume>: <fpage>519</fpage>–<lpage>527</lpage>.</citation></ref>
<ref id="bibr33-0961203313485489"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hundae</surname><given-names>A</given-names></name><name><surname>Peskoe</surname><given-names>S</given-names></name><name><surname>Grimsley</surname><given-names>E</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name></person-group>. <article-title>Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus</article-title>. <source>South Med J</source> <year>2008</year>; <volume>101</volume>: <fpage>943</fpage>–<lpage>944</lpage>.</citation></ref>
<ref id="bibr34-0961203313485489"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomietto</surname><given-names>P</given-names></name><name><surname>Gremese</surname><given-names>E</given-names></name><name><surname>Tolusso</surname><given-names>B</given-names></name><name><surname>Venturini</surname><given-names>P</given-names></name><name><surname>De Vita</surname><given-names>S</given-names></name><name><surname>Ferraccioli</surname><given-names>G</given-names></name></person-group>. <article-title>B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus</article-title>. <source>Thromb Haemost</source> <year>2004</year>; <volume>92</volume>: <fpage>1150</fpage>–<lpage>1153</lpage>.</citation></ref>
<ref id="bibr35-0961203313485489"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van den Bergh</surname><given-names>B</given-names></name><name><surname>Selleslag</surname><given-names>D</given-names></name><name><surname>Boelaert</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Management of therapy-resistant systemic lupus erythematosus with rituximab: Report of a case and review of the literature</article-title>. <source>Acta Clin Belg</source> <year>2005</year>; <volume>60</volume>: <fpage>102</fpage>–<lpage>105</lpage>.</citation></ref>
<ref id="bibr36-0961203313485489"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>ER</given-names></name><name><surname>Lander</surname><given-names>G</given-names></name><name><surname>Bidot</surname><given-names>CJ</given-names></name><name><surname>Jy</surname><given-names>W</given-names></name><name><surname>Ahn</surname><given-names>YS</given-names></name></person-group>. <article-title>Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy</article-title>. <source>Am J Hematol</source> <year>2005</year>; <volume>78</volume>: <fpage>127</fpage>–<lpage>129</lpage>.</citation></ref>
<ref id="bibr37-0961203313485489"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paran</surname><given-names>D</given-names></name><name><surname>Trej'o</surname><given-names>L</given-names></name><name><surname>Caspi</surname><given-names>D</given-names></name></person-group>. <article-title>Clinical images: B cell depletion in the appendix following rituximab treatment</article-title>. <source>Arthritis Rheum</source> <year>2006</year>; <volume>54</volume>: <fpage>2151</fpage>–<lpage>2151</lpage>.</citation></ref>
<ref id="bibr38-0961203313485489"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anandacoomarasamy</surname><given-names>A</given-names></name><name><surname>Gibson</surname><given-names>J</given-names></name><name><surname>McGill</surname><given-names>N</given-names></name></person-group>. <article-title>‘Cure’ of life-threatening antiphospholipid syndrome with rituximab</article-title>. <source>Intern Med J</source> <year>2006</year>; <volume>36</volume>: <fpage>474</fpage>–<lpage>475</lpage>.</citation></ref>
<ref id="bibr39-0961203313485489"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niewold</surname><given-names>TB</given-names></name><name><surname>Alpert</surname><given-names>D</given-names></name><name><surname>Scanzello</surname><given-names>CR</given-names></name><name><surname>Paget</surname><given-names>SA</given-names></name></person-group>. <article-title>Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease</article-title>. <source>J Rheumatol</source> <year>2006</year>; <volume>33</volume>: <fpage>1194</fpage>–<lpage>1196</lpage>.</citation></ref>
<ref id="bibr40-0961203313485489"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>KP</given-names></name><name><surname>Cambridge</surname><given-names>G</given-names></name><name><surname>Leandro</surname><given-names>MJ</given-names></name><name><surname>Edwards</surname><given-names>JC</given-names></name><name><surname>Ehrenstein</surname><given-names>M</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response</article-title>. <source>Ann Rheum Dis</source> <year>2007</year>; <volume>66</volume>: <fpage>1259</fpage>–<lpage>1262</lpage>.</citation></ref>
<ref id="bibr41-0961203313485489"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Limal</surname><given-names>N</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name><name><surname>Sène</surname><given-names>D</given-names></name><name><surname>Guichard</surname><given-names>I</given-names></name><name><surname>Piette</surname><given-names>JC</given-names></name></person-group>. <article-title>Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2008</year>; <volume>17</volume>: <fpage>69</fpage>–<lpage>71</lpage>.</citation></ref>
<ref id="bibr42-0961203313485489"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukushima</surname><given-names>T</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2008</year>; <volume>17</volume>: <fpage>210</fpage>–<lpage>214</lpage>.</citation></ref>
<ref id="bibr43-0961203313485489"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kittaka</surname><given-names>K</given-names></name><name><surname>Dobashi</surname><given-names>H</given-names></name><name><surname>Baba</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab</article-title>. <source>Scand J Rheumatol</source> <year>2008</year>; <volume>37</volume>: <fpage>390</fpage>–<lpage>393</lpage>.</citation></ref>
<ref id="bibr44-0961203313485489"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nadri</surname><given-names>QJ</given-names></name></person-group>. <article-title>Rituximab to treat active SLE in a hemodialysis patient</article-title>. <source>Saudi J Kidney Dis Transpl</source> <year>2009</year>; <volume>20</volume>: <fpage>1085</fpage>–<lpage>1086</lpage>.</citation></ref>
<ref id="bibr45-0961203313485489"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>EA</given-names></name><name><surname>Athanazio</surname><given-names>DA</given-names></name><name><surname>Lima</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis</article-title>. <source>Rheumatol Int</source> <year>2009</year>; <volume>29</volume>: <fpage>469</fpage>–<lpage>475</lpage>.</citation></ref>
<ref id="bibr46-0961203313485489"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mardjuadi</surname><given-names>A</given-names></name><name><surname>Soedirman</surname><given-names>M</given-names></name><name><surname>Utoyo</surname><given-names>B</given-names></name><name><surname>Rasker</surname><given-names>JJ</given-names></name></person-group>. <article-title>Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: The first case report from Indonesia</article-title>. <source>Clin Rheumatol</source> <year>2009</year>; <volume>28</volume>(<supplement>Suppl 1</supplement>): <fpage>S27</fpage>–<lpage>S30</lpage>.</citation></ref>
<ref id="bibr47-0961203313485489"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Letchumanan</surname><given-names>P</given-names></name><name><surname>Ng</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>LH</given-names></name><name><surname>Thumboo</surname><given-names>J</given-names></name></person-group>. <article-title>A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus</article-title>. <source>Rheumatology (Oxford)</source> <year>2009</year>; <volume>48</volume>: <fpage>399</fpage>–<lpage>403</lpage>.</citation></ref>
<ref id="bibr48-0961203313485489"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lateef</surname><given-names>A</given-names></name><name><surname>Lahiri</surname><given-names>M</given-names></name><name><surname>Teng</surname><given-names>GG</given-names></name><name><surname>Vasoo</surname><given-names>S</given-names></name></person-group>. <article-title>Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>765</fpage>–<lpage>770</lpage>.</citation></ref>
<ref id="bibr49-0961203313485489"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>WJ</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Zeng</surname><given-names>XF</given-names></name><name><surname>Zhang</surname><given-names>FC</given-names></name></person-group>. <article-title>Refractory severe connective tissue disease thrombocytopenia: Is rituximab treatment effective and safe?</article-title> <source>Ann Rheum Dis</source> <year>2009</year>; <volume>68</volume>: <fpage>1077</fpage>–<lpage>1078</lpage>.</citation></ref>
<ref id="bibr50-0961203313485489"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Hsu</surname><given-names>PY</given-names></name><name><surname>Juan</surname><given-names>KC</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>WH</given-names></name><name><surname>Lai</surname><given-names>PC</given-names></name></person-group>. <article-title>Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus</article-title>. <source>Int Immunopharmacol</source> <year>2010</year>; <volume>10</volume>: <fpage>632</fpage>–<lpage>634</lpage>.</citation></ref>
<ref id="bibr51-0961203313485489"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terrier</surname><given-names>B</given-names></name><name><surname>Amoura</surname><given-names>Z</given-names></name><name><surname>Ravaud</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry</article-title>. <source>Arthritis Rheum</source> <year>2010</year>; <volume>62</volume>: <fpage>2458</fpage>–<lpage>2466</lpage>.</citation></ref>
<ref id="bibr52-0961203313485489"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niaz</surname><given-names>FA</given-names></name><name><surname>Aleem</surname><given-names>A</given-names></name></person-group>. <article-title>Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus</article-title>. <source>Saudi J Kidney Dis Transpl</source> <year>2010</year>; <volume>21</volume>: <fpage>109</fpage>–<lpage>112</lpage>.</citation></ref>
<ref id="bibr53-0961203313485489"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>García-Carrasco</surname><given-names>M</given-names></name><name><surname>Mendoza-Pinto</surname><given-names>C</given-names></name><name><surname>Sandoval-Cruz</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: A longitudinal analysis of 52 Hispanic patients</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>213</fpage>–<lpage>219</lpage>.</citation></ref>
<ref id="bibr54-0961203313485489"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Ezeonyeji</surname><given-names>AN</given-names></name><name><surname>Thomas</surname><given-names>AS</given-names></name><name><surname>Scully</surname><given-names>MA</given-names></name><name><surname>Ehrenstein</surname><given-names>MR</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: Response to rituximab and cyclophosphamide</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>1547</fpage>–<lpage>1550</lpage>.</citation></ref>
<ref id="bibr55-0961203313485489"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>LF</given-names></name><name><surname>Velásquez</surname><given-names>CJ</given-names></name><name><surname>Prieto</surname><given-names>C</given-names></name><name><surname>Mestra</surname><given-names>L</given-names></name><name><surname>Forero</surname><given-names>E</given-names></name><name><surname>Márquez</surname><given-names>JD</given-names></name></person-group>. <article-title>Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>1219</fpage>–<lpage>1226</lpage>.</citation></ref>
<ref id="bibr56-0961203313485489"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tew</surname><given-names>GW</given-names></name><name><surname>Rabbee</surname><given-names>N</given-names></name><name><surname>Wolslegel</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>146</fpage>–<lpage>157</lpage>.</citation></ref>
<ref id="bibr57-0961203313485489"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Erre</surname><given-names>GL</given-names></name><name><surname>Pardini</surname><given-names>S</given-names></name><name><surname>Faedda</surname><given-names>R</given-names></name><name><surname>Passiu</surname><given-names>G</given-names></name></person-group>. <article-title>Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: A case report and a review of literature</article-title>. <source>Lupus</source> <year>2008</year>; <volume>17</volume>: <fpage>50</fpage>–<lpage>55</lpage>.</citation></ref>
</ref-list>
</back>
</article>